Filtered By:
Condition: Thrombosis
Education: Study
Procedure: Coronary Angioplasty

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 602 results found since Jan 2013.

Five-Year Prognostic Value of DAPT Score in Older Patients undergoing Percutaneous Coronary Intervention: A Large-Sample Study in the Real World
CONCLUSION: This study suggested that in older PCI patients, the DAPT score did not show predictive value for MACCE; however, it had a certain predictive value for 5-year BARC 2, 3, or 5 bleeding.PMID:37258235 | DOI:10.5551/jat.64212
Source: Journal of Atherosclerosis and Thrombosis - May 31, 2023 Category: Cardiology Authors: Kailun Yan Pei Zhu Xiaofang Tang Yulong Li Jiawen Li Deshan Yuan Weixian Yang Yuejin Yang Runlin Gao Bo Xu Jinqing Yuan Xueyan Zhao Source Type: research

Utilization of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention
ConclusionsThe utilization of TAT following PCI among high-stroke risk AF patients steadily increased from 2011 to 2020, reaching 65.4% by the end of the study period. However, in 2020, a significant proportion of 29.4% of patients still received DAPT, indicating that many AF patients undergoing PCI did not receive adequate antithrombotic therapy.
Source: European Journal of Clinical Pharmacology - February 24, 2023 Category: Drugs & Pharmacology Source Type: research

Extended dual antiplatelet therapy following percutaneous coronary intervention in clinically important patient subgroups: a systematic review and meta-analysis
CMAJ Open. 2023 Feb 7;11(1):E118-E130. doi: 10.9778/cmajo.20210119. Print 2023 Jan-Feb.ABSTRACTBACKGROUND: Dual antiplatelet therapy (DAPT) is routinely given to patients after percutaneous coronary intervention (PCI) with stenting; however, optimal duration remains uncertain in some situations. We assessed the benefits and harms of extending DAPT beyond 1 year after PCI in clinically important patient subgroups.METHODS: We conducted a systematic review and meta-analysis. We searched electronic databases (Embase, MEDLINE, PubMed, Cochrane Library) and grey literature (from inception to Nov. 5, 2021) and included randomized...
Source: cmaj - February 7, 2023 Category: General Medicine Authors: Jesse Elliott Shannon E Kelly Zemin Bai Becky Skidmore Michel Boucher Derek So George A Wells Source Type: research

Single antiplatelet therapy directly after percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome patients: the OPTICA study
CONCLUSIONS: This study provides first-in-human evidence that P2Y12 inhibitor monotherapy directly following PCI for NSTE-ACS is feasible, without any overt safety concerns, and highlights the need for randomised controlled trials comparing direct P2Y12 inhibitor monotherapy with the current standard of care.PMID:36734020 | DOI:10.4244/EIJ-D-22-00886
Source: EuroIntervention - February 3, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Niels M R van der Sangen Bimmer E P M Claessen I Tarik K üçük Alexander W den Hartog Jan Baan Marcel A M Beijk Ronak Delewi Tim P van de Hoef Paul Knaapen Jorrit S Lemkes Koen M Marques Alexander Nap Niels J W Verouden M Marije Vis Robbert J de Winter Source Type: research

Safety and efficacy of shortened dual antiplatelet therapy after complex percutaneous coronary intervention: A systematic review and meta - analysis
CONCLUSION: Shortened DAPT signifcantly reduced the odds of major bleedings in patients undergoing complex PCI, without increasing the ischemic events or mortality. Thus, it could be considered as a safe and feasible option in such patients.PMID:36736730 | DOI:10.1016/j.hjc.2023.01.005
Source: Hellenic Journal of Cardiology - February 3, 2023 Category: Cardiology Authors: Anastasios Apostolos Dimitrios Chlorogiannis Georgios Vasilagkos Konstantinos Katsanos Konstantinos Toutouzas Adel Aminian Dimitrios Alexopoulos Periklis Davlouros Grigorios Tsigkas Source Type: research

Single antiplatelet therapy directly after percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome patients: the OPTICA study
CONCLUSIONS: This study provides first-in-human evidence that P2Y12 inhibitor monotherapy directly following PCI for NSTE-ACS is feasible, without any overt safety concerns, and highlights the need for randomised controlled trials comparing direct P2Y12 inhibitor monotherapy with the current standard of care.PMID:36734020 | DOI:10.4244/EIJ-D-22-00886
Source: EuroIntervention - February 3, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Niels M R van der Sangen Bimmer E P M Claessen I Tarik K üçük Alexander W den Hartog Jan Baan Marcel A M Beijk Ronak Delewi Tim P van de Hoef Paul Knaapen Jorrit S Lemkes Koen M Marques Alexander Nap Niels J W Verouden M Marije Vis Robbert J de Winter Source Type: research